FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial?
FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.